A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil) to Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme
Aims:
The purpose of this study is to determine if taking the drug armodafinil will improve problems with fatigue in patients with glioblastoma and to evaluate the effects of taking armodafinil as compared to placebo on cancer related fatigue and on cognitive function.
Principal Investigator:
Ryan T. Merrell, MD
IRB Approval Number:
EH13-248
Funding Source:
Alliance for Clinical Trials in Oncology (Alliance)
Contact:
Please call 847.570.2025 with questions regarding the study
Open to Enrollment:
Yes

Expanded Access (Compassionate Use) Treatment Protocol Rindopepmut (CDX110)
Aim: This protocol has been developed to offer expanded access to rindopepimut to patients who do not qualify for enrollment into an open trial of rindopepimut or where the closest open clinical trial site is geographically inaccessible.
Principal Investigator: Ryan Merrell, MD
IRB Approval Number: EH12-370
Funding Source: Celldex Therapeutics Inc.
Contact: Please call 847.570.2025 with questions regarding the study
Open to enrollment: Yes

A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, Alliance IND# 15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Aims: The purpose of this research study is to evaluate whether the addition HSPPC-96 to bevacizumab can improve the overall survival in patients with resectable recurrent glioblastoma.
Principal Investigator: Ryan T. Merrell, MD
IRB Approval Number:
EH13-264
Funding Source:
Alliance for Clinical Trials in Oncology (Alliance)
Contact:
Please call 847.570.2025 with questions regarding the study
Open to Enrollment:
Yes 

Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained High Grade Gliomas
Aims: The purpose of this study is to assess the use of a yellow, fluorescent dye in combination with a specialized microscope during brain surgery for the removal of a specific type of tumor called a high-grade glioma. Objectives include measuring patient outcomes and measuring the extent of tumor removal.
Principal Investigator: Julian Bailes, MD
IRB Approval Number:
EH13-331
Funding Source:
NorthShore University HealthSystem
Contact:
Please call Robert Frech at 847.570.4224 with questions regarding the study
Open to Enrollment:
Yes

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 in Combination with Radiation Plus Temozolomide or Temozolomide Alone for Subjects with Glioblastoma Multiforme
Aims
: The purpose of this study is to determine how the drug ABT-414 works in the body and evaluate its safety in patients with newly diagnosed or recurrent glioblastoma.
Principal Investigator: Ryan T. Merrell, MD
IRB Approval Number: EH13-332
Funding Source: AbbVie
Contact: Please call 847.570.2025 with questions regarding the study
Open to Enrollment
: Yes

BTTC12-01: A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab
Aim:
The purpose of this study is to learn if pazopanib when given in combination with topotecan can help to control glioblastoma. The safety of this drug combination will also be studied. 
Principal Investigator: Nina Martinez, MD
IRB Approval Number: EH13-460
Funding Soure: Brain Tumor Trials Collaborative (BTTC)
Contact: Please call 847.570.2025 with questions regarding the study
Open to Enrollment: Yes

A071102: A Phase II/III Randomized Trial Of Veliparib Or Placebo In Combination With Adjuvant Temozolomide In Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Aims: The purpose of this study is to compare the effects, good or bad of the usual treatment (temozolomide) with or without the addition of the investigational drug veliparib for people whose brain tumors show a change in a small region of DNA (gene) called O6-methylguanine methyltransferase (MGMT).
Principal Investigator: Ryan Merrell, MD
IRB Approval Number: EH15-186
Funding Source: Alliance for Clinical Trials in Oncology/AbbVie
Contact: Please call 847.570.2025 with questions regarding the study.
Open to Enrollment: Yes

A Phase 2/3 Randomized, Open‑Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Aims: The primary objective of this study is to compare the overall survival of subjects treated with Toca 511 combined with Toca FC to subjects treated according to standard of care after tumor resection for recurrence of glioblastoma or anaplastic astrocytoma.
Principal Investigator: Ryan Merrell, MD
IRB Approval Number: EH15-156
Funding Source: Tocagen Inc.
Contact: Please call 847.570.2025 with questions regarding the study.
Open to Enrollment: Yes

A Phase III randomized double-blind, controlled study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy
Aim: The primary objective is to determine the overall survival of subjects treated with ICT-107 and SOC (RT and temozolomide) vs. placebo control and SOC (RT and temozolomide
Principal Investigator: Nina Martinez, MD
IRB Approval Number: EH15-230
Funding Source: ImmunoCellular Therapeutics, Ltd.
Contact: Please call 847.570.2025 with questions regarding the study.
Open to Enrollment: Yes

A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1)
Aim: The primary objective of Phase 2b is to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide plus adjuvant temozolomide prolongs Progression Free Survival (PFS) among subjects with newly diagnosed GBM harbouring EGFR amplification. The primary objective of Phase 3 is to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide plus adjuvant temozolomide prolongs Overall Survival (OS) among subjects with newly diagnosed GBM harbouring EGFR amplification.
Principal Investigator: Ryan Merrell, MD
IRB Approval Number: EH16-003
Funding Source: AbbVie Inc.
Contact: Please call 847.570.2025 with questions regarding the study.
Open to Enrollment: Yes

Molecular Analysis for Therapy Choice (MATCH)
Aim: The study is designed to assign targeted treatment based on a biopsy obtained just before study entry.
Principal Investigator: James Ward, MD
IRB Approval Number: EH15-387
Funding Source: National Cancer Institute (NCI), ECOG-ACRIN Cancer Research Group
Contact: Please call 847.570.2025 with questions regarding the study.
Open to Enrollment: Soon

× Alternate Text